Eagle Pharmaceuticals Inc (EGRX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Eagle Pharmaceuticals Inc (EGRX) is down 12.1% since the beginning of the year. At $1 per share, EGRX is trading 84.1% below its 52-week high of $4. Investors who bought $1,000 worth of EGRX shares 5 years ago would now be looking at an investment worth $15.

Eagle Pharmaceuticals Inc (EGRX) has returned -12.14% so far this year and -78.61% over the past 12 months. Over the last ten years, EGRX has returned -33.50% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Feb 12, 2014, EGRX's average daily return is +0.52%, while the average monthly return is +1.60%. At this rate, an investment would double in approximately 3.6 years.

Historically, 52% of months were positive and 48% were negative. The best month was Mar 2026 with a return of +127.4%, while the worst month was Oct 2024 at -83.9%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 5 months.

On a daily basis, EGRX closed higher 46% of trading days. The best single day was Mar 19, 2026 with a return of +750.0%, while the worst single day was Mar 17, 2026 at -97.1%.

Eagle Pharmaceuticals Inc has an annualized alpha of 234.95%, beta of 0.67, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since February 12, 2014.

• This stock participated in 142.46% of S&P 500 Index downside but only -8.38% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.67 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

EGRX ranks 53 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Eagle Pharmaceuticals Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Eagle Pharmaceuticals Inc was 99.99%, occurring on Mar 17, 2026. The portfolio has not yet recovered.

The current Eagle Pharmaceuticals Inc drawdown is 99.39%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Eagle Pharmaceuticals Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Eagle Pharmaceuticals Inc is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.